Trending...
- Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
- New Report Reveals Surprising Trends in Ohio Airport Accidents
- WCC Kitchens and Cabinets Featured on Selling Houses Australia
Proposed five-year agreement positions Covalent Medical to commercialize ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye portfolio across physician-dispensed and national retail channels, with launch targeted for Q1 2027
DALLAS - PrAtlas -- ClearSight Therapeutics Signs Letter of Intent with Covalent Medical to Expand OTC Eye Care Portfolio Through Multi-Channel Commercial Partnership
DALLAS, TX — [February 24, 2026] — ClearSight Therapeutics, Inc., an innovator in over-the-counter ophthalmic solutions, today announced the signing of a non-binding Letter of Intent (LOI) with Covalent Medical, LLC to establish a private-label manufacturing and supply partnership for ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye Products.
Under the proposed partnership, Covalent Medical intends to commercialize ClearSight's portfolio through both physician-dispensed and retail channels. The products will be introduced under Covalent's existing professional brand, Focus Tears, distributed directly through eye care practices nationwide, as well as under a new retail-focused brand targeting major national retailers.
Illustrative projections included in the LOI outline a potential five-year commercial relationship valued at approximately $60 million, reflecting anticipated product volumes across both clinical and retail markets.
The parties are currently negotiating definitive terms, with initial commercial launch anticipated in Q1 2027.
More on PrAtlas
"This agreement represents a significant milestone for ClearSight and validates both our product portfolio and manufacturing platform," said Patrick Smale, CEO of ClearSight Therapeutics. "Covalent's leadership, commercial infrastructure, and deep relationships across eye care providers and retail partners position them to accelerate market adoption of our OTC ophthalmic solutions."
Clint Worley, COO of Covalent Medical, added, "ClearSight's portfolio aligns closely with our strategy to expand across both professional and consumer channels. Their manufacturing expertise and regulatory foundation provide an ideal platform for building differentiated eye care brands."
Bob Zatarain, Head of Sales and Business Development and Board Member at Covalent Medical, commented, "Having spent over two decades in the ophthalmic industry, I recognize the importance of delivering accessible, high-quality OTC solutions. This partnership strengthens Covalent's ability to serve both practitioners and patients with innovative, compliant products."
Dr. Kairy Barazi, Founder and CEO of Covalent Medical, added, "Our focus has always been on identifying clinically grounded solutions that meet real patient needs. ClearSight's approach to product development and quality aligns well with our long-term vision for expanding access to modern eye care."
Under the proposed structure, ClearSight will retain responsibility for manufacturing, quality assurance, and regulatory compliance, while Covalent will oversee branding, packaging, and commercialization across designated channels.
More on PrAtlas
The companies intend to finalize a definitive agreement later this year, with commercialization targeted for 2027.
About ClearSight Therapeutics
Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. With a patient-first approach, the company is dedicated to making OTC eye care products that are safe, effective, and accessible to all. For more information visit www.clearsighttx.com.
About Covalent Medical
Covalent Medical, LLC was formed by over 400 retina specialists in 2011 and is one of the largest commercial organization of retina specialists in the country. Covalent Medical, which owns the brands name Focus Vitamins and SightGuardian, is a patient-focused company that produces research-based eye vitamins and OTC products with a focus on quality and safety, and are sold directly through eyecare professionals, on-line retailers, and on their website. For more information, visit www.focusvitamins.com.
# # #
Media Contact(s):
ClearSight - Patrick Smale, CEO
972-983-7761
patrick@clearsighttx.com
Covalent Medical – Clint Worley, COO
703-832-5869
cworley@focusvitamins.com
DALLAS, TX — [February 24, 2026] — ClearSight Therapeutics, Inc., an innovator in over-the-counter ophthalmic solutions, today announced the signing of a non-binding Letter of Intent (LOI) with Covalent Medical, LLC to establish a private-label manufacturing and supply partnership for ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye Products.
Under the proposed partnership, Covalent Medical intends to commercialize ClearSight's portfolio through both physician-dispensed and retail channels. The products will be introduced under Covalent's existing professional brand, Focus Tears, distributed directly through eye care practices nationwide, as well as under a new retail-focused brand targeting major national retailers.
Illustrative projections included in the LOI outline a potential five-year commercial relationship valued at approximately $60 million, reflecting anticipated product volumes across both clinical and retail markets.
The parties are currently negotiating definitive terms, with initial commercial launch anticipated in Q1 2027.
More on PrAtlas
- Colony Ridge Communities Celebrates Successful Soccer Season Kickoff with Families and Youth
- EFA Announces 2026 Editorial Rate Chart
- NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
- Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming
- Shoutout Joseph Neibich aka Nybyk
"This agreement represents a significant milestone for ClearSight and validates both our product portfolio and manufacturing platform," said Patrick Smale, CEO of ClearSight Therapeutics. "Covalent's leadership, commercial infrastructure, and deep relationships across eye care providers and retail partners position them to accelerate market adoption of our OTC ophthalmic solutions."
Clint Worley, COO of Covalent Medical, added, "ClearSight's portfolio aligns closely with our strategy to expand across both professional and consumer channels. Their manufacturing expertise and regulatory foundation provide an ideal platform for building differentiated eye care brands."
Bob Zatarain, Head of Sales and Business Development and Board Member at Covalent Medical, commented, "Having spent over two decades in the ophthalmic industry, I recognize the importance of delivering accessible, high-quality OTC solutions. This partnership strengthens Covalent's ability to serve both practitioners and patients with innovative, compliant products."
Dr. Kairy Barazi, Founder and CEO of Covalent Medical, added, "Our focus has always been on identifying clinically grounded solutions that meet real patient needs. ClearSight's approach to product development and quality aligns well with our long-term vision for expanding access to modern eye care."
Under the proposed structure, ClearSight will retain responsibility for manufacturing, quality assurance, and regulatory compliance, while Covalent will oversee branding, packaging, and commercialization across designated channels.
More on PrAtlas
- Meet Joseph Neibich aka Joseph Nybyk of Beachwood Canyon
- LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
- KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
The companies intend to finalize a definitive agreement later this year, with commercialization targeted for 2027.
About ClearSight Therapeutics
Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. With a patient-first approach, the company is dedicated to making OTC eye care products that are safe, effective, and accessible to all. For more information visit www.clearsighttx.com.
About Covalent Medical
Covalent Medical, LLC was formed by over 400 retina specialists in 2011 and is one of the largest commercial organization of retina specialists in the country. Covalent Medical, which owns the brands name Focus Vitamins and SightGuardian, is a patient-focused company that produces research-based eye vitamins and OTC products with a focus on quality and safety, and are sold directly through eyecare professionals, on-line retailers, and on their website. For more information, visit www.focusvitamins.com.
# # #
Media Contact(s):
ClearSight - Patrick Smale, CEO
972-983-7761
patrick@clearsighttx.com
Covalent Medical – Clint Worley, COO
703-832-5869
cworley@focusvitamins.com
Source: ClearSight Therapeutics, Inc.
0 Comments
Latest on PrAtlas
- Tony Grundler Introduces Artificial Intelligence V.S. Avatar-Ian's
- Hollywood's Elite Gather at the Annual WOW Creations Oscars Gifting Suite at the Universal Hilton
- Where Were the Women? Reframing the Greek Revolution Through Contemporary Art
- JGCMGS Details Architecture to Safeguard Assets From Unauthorized Phishing Scams
- 21 Days: The Malta Deadline That Could Redraw the Finnish Online Casino Map
- JEGS Launches Modern, Secure Payments Powered by PhaseZero.ai
- U.S. Government Contracts in Excess of 38 Million Secured Through Partner, Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
- New Report Reveals Surprising Trends in Ohio Airport Accidents
- Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
- WCC Kitchens and Cabinets Featured on Selling Houses Australia
- Cat Hunt Simulator : Burrow & Pounce Lands on the App Store
- Shincheonji Marks 42nd Anniversary: From a Basement to a Denomination Growing by Tens of Thousands Annually
- Jackets for Jobs Hosts Smart & Sexy® Day Detroit for Women's History Month
- Tint Academy Training in Dallas Texas: Learn Window Tint & PPF Installation
- $IBG accelerates toward transformative merger with BlockFuel as $6 million raise fuels dual-industry growth strategy: N A S D A Q: IBG
- High-Growth Power Infrastructure Play Targets AI Boom: 1606 Corp. Executes Aggressive Texas Expansion Strategy: 1606 Corp. (Stock Symbol: CBDW) $CBDW
- Accelerating the Transformation into a U.S. Nuclear Fuel Cycle Leader: Frontier Nuclear and Minerals Inc. (N A S D A Q: FNUC)
- Ozz Metals Ltd Secures 1-Tonne Gold Offtake Agreement
- Jet Set: The Ultimate Coachella Afterparty
- Heritage at Manalapan Introduces New Single-Family Home Community in One of Monmouth County's Most Desirable Locations